NCT02483325View on ClinicalTrials.gov

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2020

Conditions
Hematological Diseases
Interventions
DRUG

Allogeneic transplant conditioning

Allogeneic transplant

Trial Locations (1)

13009

Institut Paoli Calmettes, Marseille

All Listed Sponsors
collaborator

Agence de La Biomédecine

OTHER_GOV

lead

Institut Paoli-Calmettes

OTHER

NCT02483325 - Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases | Biotech Hunter | Biotech Hunter